Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 17
HOS-086261 · Präparat HOS-083284
25-O-desacetyl rifabutin metabolite ↑ 38-fold ↑ 16-fold
The reduction of the rifabutin dose to 150 mg 3 times per week may be indicated for
select PIs when co-administered with ritonavir as a pharmacokinetic enhancer. The
SmPC of the co-administered protease inhibitor should be consulted for specific
recommendations. Consideration should be given to official guidance on the
appropriate treatment of tuberculosis in HIV-infected patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): protease (HOS-085623) rifabutin (HOS-086262)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage fe84a0e7ca99bea0f3c97164dd343af80514da25198a10b2d277396d90200a02 · Zeichen 30295–30981 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 49
HOS-086446 · Präparat HOS-083284
25-O-desacetyl rifabutin metabolite ↑ 38-fold ↑ 16-fold
The reduction of the rifabutin dose to 150 mg 3 times per week may be indicated for
select PIs when co-administered with ritonavir as a pharmacokinetic enhancer. The
SmPC of the co-administered protease inhibitor should be consulted for specific
recommendations. Consideration should be given to official guidance on the appropriate
treatment of tuberculosis in HIV-infected patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): protease (HOS-085623) rifabutin (HOS-086262)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage f07a40ac07c9e1f860aa280090b30e24b0b3f15500c36b0f3e6d08f873b1f061 · Zeichen 31344–32039 im Abschnitt
Wechselwirkungen · Viramune
Viramune 200 mg tablets · Abschnitt 4.5 · PDF-Seite 12–13
HOS-088114 · Präparat HOS-083615
12
Rifabutin Rifabutin AUC 1.17 (0.98-1.40) No significant effect on rifabutin
150 or 300 mg QD Rifabutin Cmin 1.07 (0.84-1.37) and Viramune mean PK parameters
Rifabutin Cmax 1.28 (1.09-1.51) is seen. Rifabutin and Viramune
can be co-administered without
Metabolite 25-O-desacetylrifabutin dose adjustments. However, due to
AUC 1.24 (0.84-1.84) the high interpatient variability
Metabolite 25-O-desacetylrifabutin some patients may experience large
Cmin 1.22 (0.86-1.74) increases in rifabutin exposure and
Metabolite 25-O-desacetylrifabutin may be at higher risk for rifabutin
Cmax 1.29 (0.98-1.68) toxicity. Therefore, caution should
be used in concomitant
A clinically not relevant increase administration.
in the apparent clearance of
nevirapine (by 9%) compared to
historical data was reported.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifabutin (HOS-086262)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage 351e8045ee941840fc49597fe66dff702125e88f83a3b4f905289093ff288993 · Zeichen 14842–16068 im Abschnitt
Wechselwirkungen · Viramune
Viramune 200 mg tablets · Abschnitt 4.5 · PDF-Seite 13
HOS-088115 · Präparat HOS-083615
Rifampicin Rifampicin AUC 1.11 It is not recommended to co-
600 mg QD (0.96-1.28) administer rifampicin and
Rifampicin Cmin ND Viramune (see section 4.4).
Rifampicin Cmax 1.06 Physicians needing to treat patients
(0.91-1.22) co-infected with tuberculosis and
using a Viramune containing
Nevirapine AUC 0.42 regimen may consider co-
Nevirapine Cmin 0.32 administration of rifabutin instead.
Nevirapine Cmax 0.50
compared to historical controls.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifabutin (HOS-086262)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage 5eb86c28f9091771b2b6092a785d2056c1bd953cf2f1d0deb6650927f258a832 · Zeichen 16070–16871 im Abschnitt
Wechselwirkungen · Viramune
Viramune 200 mg tablets · Abschnitt 4.5 · PDF-Seite 16
HOS-088140 · Präparat HOS-083615
Nevirapine metabolites: Studies using human liver microsomes indicated that the formation of
nevirapine hydroxylated metabolites was not affected by the presence of dapsone, rifabutin,
rifampicin, and trimethoprim/sulfamethoxazole. Ketoconazole and erythromycin significantly
inhibited the formation of nevirapine hydroxylated metabolites.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) trimethoprim (HOS-085184) ketoconazole (HOS-084513) rifabutin (HOS-086262) erythromycin (HOS-084514) dapsone (HOS-088141)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage 287f611aa6814b77da2d4566909fd98bfac0e60816895edf476ea11c81f8affa · Zeichen 25397–25736 im Abschnitt
Wechselwirkungen · Viramune
Viramune 50 mg/5 mL oral suspension · Abschnitt 4.5 · PDF-Seite 37
HOS-088211 · Präparat HOS-083615
Rifabutin Rifabutin AUC 1.17 (0.98-1.40) No significant effect on rifabutin
150 or 300 mg QD Rifabutin Cmin 1.07 (0.84-1.37) and Viramune mean PK parameters
Rifabutin Cmax 1.28 (1.09-1.51) is seen. Rifabutin and Viramune
can be co-administered without
Metabolite 25-O-desacetylrifabutin dose adjustments. However, due to
AUC 1.24 (0.84-1.84) the high interpatient variability
Metabolite 25-O-desacetylrifabutin some patients may experience large
Cmin 1.22 (0.86-1.74) increases in rifabutin exposure and
Metabolite 25-O-desacetylrifabutin may be at higher risk for rifabutin
Cmax 1.29 (0.98-1.68) toxicity. Therefore, caution should
be used in concomitant
A clinically not relevant increase administration.
in the apparent clearance of
nevirapine (by 9%) compared to
historical data was reported.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifabutin (HOS-086262)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage 82b7af5d46ec1bd51b5881ff9f72e4eaea7695238e88a7df8e0b04b53ae92583 · Zeichen 14852–16050 im Abschnitt
Wechselwirkungen · Viramune
Viramune 50 mg/5 mL oral suspension · Abschnitt 4.5 · PDF-Seite 37
HOS-088212 · Präparat HOS-083615
Rifampicin Rifampicin AUC 1.11 It is not recommended to co-
600 mg QD (0.96-1.28) administer rifampicin and
Rifampicin Cmin ND Viramune (see section 4.4).
Rifampicin Cmax 1.06 Physicians needing to treat patients
(0.91-1.22) co-infected with tuberculosis and
using a Viramune containing
Nevirapine AUC 0.42 regimen may consider co-
Nevirapine Cmin 0.32 administration of rifabutin instead.
Nevirapine Cmax 0.50
compared to historical controls.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifabutin (HOS-086262)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage 6d30f1d972e0aa6cceb301478c23bf515e7852df3a6dc11a252defa05011e7b2 · Zeichen 16052–16837 im Abschnitt
Wechselwirkungen · Viramune
Viramune 50 mg/5 mL oral suspension · Abschnitt 4.5 · PDF-Seite 40
HOS-088231 · Präparat HOS-083615
Nevirapine metabolites: Studies using human liver microsomes indicated that the formation of
nevirapine hydroxylated metabolites was not affected by the presence of dapsone, rifabutin,
rifampicin, and trimethoprim/sulfamethoxazole. Ketoconazole and erythromycin significantly
inhibited the formation of nevirapine hydroxylated metabolites.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) trimethoprim (HOS-085184) ketoconazole (HOS-084513) rifabutin (HOS-086262) erythromycin (HOS-084514) dapsone (HOS-088141)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage 287f611aa6814b77da2d4566909fd98bfac0e60816895edf476ea11c81f8affa · Zeichen 25548–25887 im Abschnitt
Wechselwirkungen · Viramune
Viramune 400 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 62–63
HOS-088303 · Präparat HOS-083615
62
Rifabutin Rifabutin AUC 1.17 (0.98-1.40) No significant effect on rifabutin
150 or 300 mg QD Rifabutin Cmin 1.07 (0.84-1.37) and Viramune mean PK parameters
Rifabutin Cmax 1.28 (1.09-1.51) is seen. Rifabutin and Viramune
can be co-administered without
Metabolite 25-O-desacetylrifabutin dose adjustments. However, due to
AUC 1.24 (0.84-1.84) the high interpatient variability
Metabolite 25-O-desacetylrifabutin some patients may experience large
Cmin 1.22 (0.86-1.74) increases in rifabutin exposure and
Metabolite 25-O-desacetylrifabutin may be at higher risk for rifabutin
Cmax 1.29 (0.98-1.68) toxicity. Therefore, caution should
be used in concomitant
A clinically not relevant increase administration.
in the apparent clearance of
nevirapine (by 9%) compared to
historical data was reported.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifabutin (HOS-086262)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage 9977b0f0223881e2ecae37f51be726186b1d79b22acc41cbebf685bbc2bf8959 · Zeichen 15062–16288 im Abschnitt
Wechselwirkungen · Viramune
Viramune 400 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 63
HOS-088304 · Präparat HOS-083615
Rifampicin Rifampicin AUC 1.11 It is not recommended to co-
600 mg QD (0.96-1.28) administer rifampicin and
Rifampicin Cmin ND Viramune (see section 4.4).
Rifampicin Cmax 1.06 Physicians needing to treat patients
(0.91-1.22) co-infected with tuberculosis and
using a Viramune containing
Nevirapine AUC 0.42 regimen may consider co-
Nevirapine Cmin 0.32 administration of rifabutin instead.
Nevirapine Cmax 0.50
compared to historical controls.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifabutin (HOS-086262)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage 5eb86c28f9091771b2b6092a785d2056c1bd953cf2f1d0deb6650927f258a832 · Zeichen 16290–17091 im Abschnitt
Wechselwirkungen · Viramune
Viramune 400 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 66
HOS-088321 · Präparat HOS-083615
Nevirapine metabolites: Studies using human liver microsomes indicated that the formation of
nevirapine hydroxylated metabolites was not affected by the presence of dapsone, rifabutin,
rifampicin, and trimethoprim/sulfamethoxazole. Ketoconazole and erythromycin significantly
inhibited the formation of nevirapine hydroxylated metabolites.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) trimethoprim (HOS-085184) ketoconazole (HOS-084513) rifabutin (HOS-086262) erythromycin (HOS-084514) dapsone (HOS-088141)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage 287f611aa6814b77da2d4566909fd98bfac0e60816895edf476ea11c81f8affa · Zeichen 25483–25822 im Abschnitt
Wechselwirkungen · Rapamune
Rapamune 1 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 8
HOS-090592 · Präparat HOS-084095
Sirolimus is extensively metabolised by the CYP3A4 isozyme in the intestinal wall and liver.
Sirolimus is also a substrate for the multidrug efflux pump, P-glycoprotein (P-gp) located in the small
intestine. Therefore, absorption and the subsequent elimination of sirolimus may be influenced by
substances that affect these proteins. Inhibitors of CYP3A4 (such as ketoconazole, voriconazole,
itraconazole, telithromycin, or clarithromycin) decrease the metabolism of sirolimus and increase
sirolimus levels. Inducers of CYP3A4 (such as rifampin or rifabutin) increase the metabolism of
sirolimus and decrease sirolimus levels. Co-administration of sirolimus with strong inhibitors of
CYP3A4 or inducers of CYP3A4 is not recommended (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifampin (HOS-088791) ketoconazole (HOS-084513) rifabutin (HOS-086262) voriconazole (HOS-084524) telithromycin (HOS-084523) itraconazole (HOS-084516) clarithromycin (HOS-084517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-04T09:34:00Z · SHA-256 822914cb553b9bcf81064d714c9274d63e73d083445521dca5c314d6106f24d7 · Passage 159852d4b6d56d956ff9fb4bd74e5bc0c13922c9c8af0ccc6125f8aa005e10e7 · Zeichen 0–750 im Abschnitt
Wechselwirkungen · Rapamune
Rapamune 0.5 mg coated tablets Rapamune 1 mg coated tablets Rapamune 2 mg coated tablets · Abschnitt 4.5 · PDF-Seite 29
HOS-090664 · Präparat HOS-084095
Sirolimus is extensively metabolised by the CYP3A4 isozyme in the intestinal wall and liver.
Sirolimus is also a substrate for the multidrug efflux pump, P-glycoprotein (P-gp) located in the small
intestine. Therefore, absorption and the subsequent elimination of sirolimus may be influenced by
substances that affect these proteins. Inhibitors of CYP3A4 (such as ketoconazole, voriconazole,
itraconazole, telithromycin, or clarithromycin) decrease the metabolism of sirolimus and increase
sirolimus levels. Inducers of CYP3A4 (such as rifampin or rifabutin) increase the metabolism of
sirolimus and decrease sirolimus levels. Co-administration of sirolimus with strong inhibitors of
CYP3A4 or inducers of CYP3A4 is not recommended (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifampin (HOS-088791) ketoconazole (HOS-084513) rifabutin (HOS-086262) voriconazole (HOS-084524) telithromycin (HOS-084523) itraconazole (HOS-084516) clarithromycin (HOS-084517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-04T09:34:00Z · SHA-256 822914cb553b9bcf81064d714c9274d63e73d083445521dca5c314d6106f24d7 · Passage 159852d4b6d56d956ff9fb4bd74e5bc0c13922c9c8af0ccc6125f8aa005e10e7 · Zeichen 0–750 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 18–19
HOS-108902 · Präparat HOS-093083
18
Delamanid (100 mg BID) Delamanid: Due to the risk of QTc prolongation
AUC: ↑ 22% associated with DM-6705, if
(Lopinavir/ritonavir co-administration of delamanid
400/100 mg BID) DM-6705 (delamanid active with Kaletra is considered
metabolite): necessary, very frequent ECG
AUC: ↑ 30% monitoring throughout the full
delamanid treatment period is
A more pronounced effect on recommended (see section 4.4 and
DM-6705 exposure may be refer to the delamanid SmPC).
observed during prolonged co-
administration with
lopinavir/ritonavir.
Rifabutin, 150 mg QD Rifabutin (parent drug and active When given with Kaletra the
25-O-desacetyl metabolite): recommended dose of rifabutin is
AUC: ↑ 5.7-fold 150 mg 3 times per week on set
Cmax: ↑ 3.5-fold days (for example Monday-
Wednesday-Friday). Increased
monitoring for rifabutin-associated
adverse reactions including
neutropenia and uveitis is
warranted due to an expected
increase in exposure to rifabutin.
Further dosage reduction of
rifabutin to 150 mg twice weekly
on set days is recommended for
patients in whom the 150 mg dose 3
times per week is not tolerated. It
should be kept in mind that the
twice weekly dosage of 150 mg
may not provide an optimal
exposure to rifabutin thus leading to
a risk of rifamycin resistance and a
treatment failure. No dose
adjustment is needed for Kaletra.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifabutin (HOS-086262)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 4d0e570f83c31ad6e7d6d9069d780bca8dd15316d14421515d881b102d611006 · Zeichen 35319–38324 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 54–55
HOS-109014 · Präparat HOS-093083
54
Delamanid (100 mg Delamanid: Due to the risk of QTc prolongation
BID) AUC: ↑ 22% associated with DM-6705, if
co-administration of delamanid with
(Lopinavir/ritonavir DM-6705 (delamanid active Kaletra is considered necessary, very
400/100 mg BID) metabolite): frequent ECG monitoring throughout
AUC: ↑ 30% the full delamanid treatment period is
recommended (see section 4.4 and
A more pronounced effect on refer to the delamanid SmPC).
DM-6705 exposure may be
observed during prolonged co-
administration with
lopinavir/ritonavir.
Rifabutin, 150 mg QD Rifabutin (parent drug and active When given with Kaletra the
25-O-desacetyl metabolite): recommended dose of rifabutin is
AUC: ↑ 5.7-fold 150 mg 3 times per week on set days
Cmax: ↑ 3.5-fold (for example Monday-Wednesday-
Friday). Increased monitoring for
rifabutin-associated adverse reactions
including neutropenia and uveitis is
warranted due to an expected increase
in exposure to rifabutin. Further
dosage reduction of rifabutin to
150 mg twice weekly on set days is
recommended for patients in whom
the 150 mg dose 3 times per week is
not tolerated. It should be kept in
mind that the twice weekly dosage of
150 mg may not provide an optimal
exposure to rifabutin thus leading to a
risk of rifamycin resistance and a
treatment failure. No dose
adjustment is needed for Kaletra.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifabutin (HOS-086262)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 3cbad450d5aaf94df5969585613bcbf202c0aeee9e962dac91a0441eeb6ee471 · Zeichen 34292–37099 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 90–91
HOS-109091 · Präparat HOS-093083
90
Rifabutin, 150 mg QD Rifabutin (parent drug and active When given with Kaletra the
25-O-desacetyl metabolite): recommended dose of rifabutin is
AUC: ↑ 5.7-fold 150 mg 3 times per week on set
Cmax: ↑ 3.5-fold days (for example Monday-
Wednesday-Friday). Increased
monitoring for rifabutin-associated
adverse reactions including
neutropenia and uveitis is warranted
due to an expected increase in
exposure to rifabutin. Further
dosage reduction of rifabutin to
150 mg twice weekly on set days is
recommended for patients in whom
the 150 mg dose 3 times per week is
not tolerated. It should be kept in
mind that the twice weekly dosage
of 150 mg may not provide an
optimal exposure to rifabutin thus
leading to a risk of rifamycin
resistance and a treatment failure.
No dose adjustment is needed for
Kaletra.
Rifampicin Lopinavir: Co-administration of Kaletra with
Large decreases in lopinavir rifampicin is not recommended as
concentrations may be observed the decrease in lopinavir
due to CYP3A induction by concentrations may in turn
rifampicin. significantly decrease the lopinavir
therapeutic effect. A dose
adjustment of Kaletra
400 mg/400 mg (i.e. Kaletra
400/100 mg + ritonavir 300 mg)
twice daily has allowed
compensating for the CYP 3A4
inducer effect of rifampicin.
However, such a dose adjustment
might be associated with ALT/AST
elevations and with increase in
gastrointestinal disorders.
Therefore, this co-administration
should be avoided unless judged
strictly necessary. If this
co-administration is judged
unavoidable, increased dose of
Kaletra at 400 mg/400 mg twice
daily may be administered with
rifampicin under close safety and
therapeutic drug monitoring. The
Kaletra dose should be titrated
upward only after rifampicin has
been initiated (see section 4.4).
Antipsychotics
Lurasidone Due to CYP3A inhibition by The concomitant administration
lopinavir/ritonavir, concentrations with lurasidone is contraindicated
of lurasidone are expected to (see section 4.3).
increase.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifabutin (HOS-086262) lurasidone (HOS-086148)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage ef631cb168a202ad49cd1e5d830eb707073235478031c2a079706957841b1d31 · Zeichen 35398–40311 im Abschnitt
Wechselwirkungen · Vfend
VFEND 50 mg film-coated tablets VFEND 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11–12
HOS-109445 · Präparat HOS-093201
Erythromycin (1 g BID) Voriconazole Cmax and AUC ↔
[CYP3A4 inhibitor]
The effect of voriconazole on
either erythromycin or
azithromycin is unknown.
Rifabutin Concomitant use of voriconazole
[potent CYP450 inducer] and rifabutin should be avoided
Voriconazole Cmax 69% unless the benefit outweighs the
300 mg QD Voriconazole AUC 78% risk.
The maintenance dose of
Compared to voriconazole 200 mg voriconazole may be increased to
300 mg QD (coadministered BID, 5 mg/kg intravenously BID or
with voriconazole 350 mg Voriconazole Cmax 4% from 200 mg to 350 mg orally
BID)* Voriconazole AUC 32% BID (100 mg to 200 mg orally
BID in patients less than 40 kg)
(see section 4.2).
Careful monitoring of full blood
Rifabutin Cmax 195% counts and adverse reactions to
300 mg QD (coadministered Rifabutin AUC 331% rifabutin (e.g., uveitis) is
with voriconazole 400 mg Compared to voriconazole 200 mg recommended when rifabutin is
BID)* BID, coadministered with
voriconazole.
Voriconazole Cmax 104%
Voriconazole AUC 87%
Rifampicin (600 mg QD) Voriconazole Cmax 93% Contraindicated (see section
[potent CYP450 inducer] Voriconazole AUC 96% 4.3)
Anti-cancer agents
Glasdegib Although not studied, voriconazole If concomitant use cannot be
[CYP3A4 substrate] is likely to increase the plasma avoided, frequent ECG
concentrations of glasdegib and monitoring is recommended (see
increase risk of QTc prolongation. section 4.4).
Tretinoin Although not studied, voriconazole Dose adjustment of tretinoin is
[CYP3A4 substrate] may increase tretinoin recommended during treatment
concentrations and increase risk of with voriconazole and after its
adverse reactions (pseudotumor discontinuation.
cerebri, hypercalcaemia).
11
Tyrosine kinase inhibitors Although not studied, voriconazole If concomitant use cannot be
(including but not limited to: may increase plasma avoided, dose reduction of the
axitinib, bosutinib, concentrations of tyrosine kinase tyrosine kinase inhibitor and
cabozantinib, ceritinib, inhibitors metabolised by CYP3A4. close clinical monitoring is
cobimetinib, dabrafenib, recommended (see section 4.4).
dasatinib, nilotinib, sunitinib,
ibrutinib, ribociclib)
[CYP3A4 substrates]
Venetoclax Although not studied, voriconazole
Concomitant administration of
[CYP3A substrate] is likely to significantly increase
voriconazole is contraindicated
the plasma concentrations of at initiation and during
venetoclax. venetoclax dose titration phase
(see section 4.3). Dose reduction
of venetoclax is required as
instructed in venetoclax
prescribing information during
steady daily dosing; close
monitoring for signs of toxicity is
recommended.
Vinca Alkaloids (including but Although not studied, voriconazole Dose reduction of vinca alkaloids
not limited to: vincristine and is likely to increase the plasma should be considered.
vinblastine) concentrations of vinca alkaloids
[CYP3A4 substrates] and lead to neurotoxicity.
Anticoagulants
Warfarin (30 mg single dose, Maximum increase in prothrombin Close monitoring of prothrombin
coadministered with 300 mg time was approximately 2-fold. time or other suitable
BID voriconazole) anticoagulation tests is
[CYP2C9 substrate] recommended, and the dose of
anticoagulants should be adjusted
Other oral coumarins Although not studied, voriconazole accordingly.
(including but not limited to: may increase the plasma
phenprocoumon, concentrations of coumarins that
acenocoumarol) may cause an increase in
[CYP2C9 and CYP3A4 prothrombin time.
substrates]
Anticonvulsants
Carbamazepine and Although not studied, Contraindicated (see section
long-acting barbiturates carbamazepine and long-acting 4.3)
(including but not limited to: barbiturates are likely to
phenobarbital, mephobarbital) significantly decrease plasma
[potent CYP450 inducers] voriconazole concentrations.
Phenytoin Concomitant use of voriconazole
[CYP2C9 substrate and potent and phenytoin should be avoided
CYP450 inducer] unless the benefit outweighs the
risk. Careful monitoring of
300 mg QD Voriconazole Cmax 49% phenytoin plasma levels is
Voriconazole AUC 69% recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): axitinib (HOS-109448) ceritinib (HOS-086215) dasatinib (HOS-086217) cobimetinib (HOS-109451) phenobarbital (HOS-085617) carbamazepine (HOS-085618) rifabutin (HOS-086262) vinblastine (HOS-086220) glasdegib (HOS-109446) vincristine (HOS-086219) azithromycin (HOS-088112) phenprocoumon (HOS-091031) dabrafenib (HOS-109452) venetoclax (HOS-086143) tretinoin (HOS-109447) lead (HOS-085592) prothrombin (HOS-085093) sunitinib (HOS-109453) erythromycin (HOS-084514) ribociclib (HOS-109454) tyrosine (HOS-108875) acenocoumarol (HOS-109456) cabozantinib (HOS-109450) phenytoin (HOS-084531) warfarin (HOS-085950) bosutinib (HOS-109449) mephobarbital (HOS-109457) nilotinib (HOS-086218) ibrutinib (HOS-086226)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 92969ff5c9d1e7ffb4a2f7eaf265abd9d2899e7061ac52ea8adefc4d660b4316 · Zeichen 4932–11582 im Abschnitt
Wechselwirkungen · Vfend
VFEND 200 mg powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 42–43
HOS-109537 · Präparat HOS-093201
42
Rifabutin Concomitant use of voriconazole
[potent CYP450 inducer] and rifabutin should be avoided
Voriconazole Cmax 69% unless the benefit outweighs the
300 mg QD Voriconazole AUC 78% risk.
The maintenance dose of
Compared to voriconazole 200 mg voriconazole may be increased to
300 mg QD (coadministered BID, 5 mg/kg intravenously BID or
with voriconazole 350 mg Voriconazole Cmax 4% from 200 mg to 350 mg orally
BID)* Voriconazole AUC 32% BID (100 mg to 200 mg orally
BID in patients less than 40 kg)
(see section 4.2).
Careful monitoring of full blood
Rifabutin Cmax 195% counts and adverse reactions to
300 mg QD (coadministered Rifabutin AUC 331% rifabutin (e.g., uveitis) is
with voriconazole 400 mg Compared to voriconazole 200 mg recommended when rifabutin is
BID)* BID, coadministered with
voriconazole.
Voriconazole Cmax 104%
Voriconazole AUC 87%
Rifampicin (600 mg QD) Voriconazole Cmax 93% Contraindicated (see section
[potent CYP450 inducer] Voriconazole AUC 96% 4.3)
Anti-cancer agents
Glasdegib Although not studied, voriconazole If concomitant use cannot be
[CYP3A4 substrate] is likely to increase the plasma avoided, frequent ECG
concentrations of glasdegib and monitoring is recommended (see
increase risk of QTc prolongation. section 4.4).
Tretinoin Although not studied, voriconazole Dose adjustment of tretinoin is
[CYP3A4 substrate] may increase tretinoin recommended during treatment
concentrations and increase risk of with voriconazole and after its
adverse reactions (pseudotumor discontinuation.
cerebri, hypercalcaemia).
Tyrosine kinase inhibitors Although not studied, voriconazole If concomitant use cannot be
(including but not limited to: may increase plasma avoided, dose reduction of the
axitinib, bosutinib, concentrations of tyrosine kinase tyrosine kinase inhibitor and
cabozantinib, ceritinib, inhibitors metabolised by CYP3A4. close clinical monitoring is
cobimetinib, dabrafenib, recommended (see section 4.4).
dasatinib, nilotinib, sunitinib,
ibrutinib, ribociclib)
[CYP3A4 substrates]
Venetoclax Although not studied, voriconazole
Concomitant administration of
[CYP3A substrate] is likely to significantly increase
voriconazole is contraindicated
the plasma concentrations of at initiation and during
venetoclax. venetoclax dose titration phase
(see section 4.3). Dose reduction
of venetoclax is required as
instructed in venetoclax
prescribing information during
steady daily dosing; close
monitoring for signs of toxicity is
recommended.
Vinca Alkaloids (including but Although not studied, voriconazole Dose reduction of vinca alkaloids
not limited to: vincristine and is likely to increase the plasma should be considered.
vinblastine) concentrations of vinca alkaloids
[CYP3A4 substrates] and lead to neurotoxicity.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): axitinib (HOS-109448) ceritinib (HOS-086215) dasatinib (HOS-086217) cobimetinib (HOS-109451) rifabutin (HOS-086262) vinblastine (HOS-086220) glasdegib (HOS-109446) vincristine (HOS-086219) dabrafenib (HOS-109452) venetoclax (HOS-086143) tretinoin (HOS-109447) lead (HOS-085592) sunitinib (HOS-109453) ribociclib (HOS-109454) tyrosine (HOS-108875) cabozantinib (HOS-109450) bosutinib (HOS-109449) nilotinib (HOS-086218) ibrutinib (HOS-086226)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 8012148fb9215ea208ca5169c42c7950e3148c6cc17fe0855dae44a2c3a5b40a · Zeichen 5353–10162 im Abschnitt
Wechselwirkungen · Vfend
VFEND 40 mg/ml powder for oral suspension · Abschnitt 4.5 · PDF-Seite 75
HOS-109601 · Präparat HOS-093201
Erythromycin (1 g BID) Voriconazole Cmax and AUC ↔
[CYP3A4 inhibitor]
The effect of voriconazole on
either erythromycin or
azithromycin is unknown.
Rifabutin Concomitant use of voriconazole
[potent CYP450 inducer] and rifabutin should be avoided
Voriconazole Cmax 69% unless the benefit outweighs the
300 mg QD Voriconazole AUC 78% risk.
The maintenance dose of
Compared to voriconazole 200 mg voriconazole may be increased to
300 mg QD (coadministered BID, 5 mg/kg intravenously BID or
with voriconazole 350 mg Voriconazole Cmax 4% from 200 mg to 350 mg orally
BID)* Voriconazole AUC 32% BID (100 mg to 200 mg orally
BID in patients less than 40 kg)
(see section 4.2).
Careful monitoring of full blood
Rifabutin Cmax 195% counts and adverse reactions to
300 mg QD (coadministered Rifabutin AUC 331% rifabutin (e.g., uveitis) is
with voriconazole 400 mg Compared to voriconazole 200 mg recommended when rifabutin is
BID)* BID, coadministered with
voriconazole.
Voriconazole Cmax 104%
Voriconazole AUC 87%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifabutin (HOS-086262) azithromycin (HOS-088112) erythromycin (HOS-084514)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 70d2842c89a0f76b2b89010da68a228ee91da2104f8948deb891ed4d807cbace · Zeichen 4948–6767 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 14–15
HOS-112085 · Präparat HOS-093615
14
Medicinal products by Interaction Recommendations concerning co-
therapeutic area administration
ANTIMYCOBACTERIAL
Rifabutin 150 mg twice weekly Rifabutin AUC: ↑48% (↑19% ↑84%)** When given with REYATAZ, the
(atazanavir 300 mg and ritonavir Rifabutin Cmax: ↑149% (↑103% ↑206%)** recommended dose of rifabutin is
100 mg once daily) Rifabutin Cmin: ↑40% (↑5% ↑87%)** 150 mg 3 times per week on set
days (for example Monday-
25-O-desacetyl-rifabutin AUC: ↑990% Wednesday-Friday). Increased
(↑714% ↑1 361%)** monitoring for rifabutin-associated
25-O-desacetyl-rifabutin Cmax: ↑677% adverse reactions including
(↑513% ↑883%)** neutropenia and uveitis is warranted
25-O-desacetyl-rifabutin Cmin: ↑1 045% due to an expected increase in
(↑715% ↑1 510%)** exposure to rifabutin. Further
dosage reduction of rifabutin to
**When compared to rifabutin 150 mg 150 mg twice weekly on set days is
once daily alone. Total rifabutin and recommended for patients in whom
25-O-desacetyl-rifabutin AUC: ↑119% the 150 mg dose 3 times per week
(↑78% ↑169%). is not tolerated. It should be kept in
mind that the twice weekly dosage
In previous studies, the pharmacokinetics of 150 mg may not provide an
of atazanavir was not altered by rifabutin. optimal exposure to rifabutin thus
leading to a risk of rifamycin
resistance and a treatment failure.
No dose adjustment is needed for
REYATAZ.
Rifampicin Rifampicin is a strong CYP3A4 inducer The combination of rifampicin and
and has been shown to cause a 72% REYATAZ is contraindicated
decrease in atazanavir AUC which can (see section 4.3).
result in virological failure and resistance
development. During attempts to
overcome the decreased exposure by
increasing the dose of REYATAZ or other
protease inhibitors with ritonavir, a high
frequency of liver reactions was seen.
ANTIPSYCHOTICS
Quetiapine Due to CYP3A4 inhibition by REYATAZ, Co-administration of quetiapine
concentrations of quetiapine are expected with REYATAZ is contraindicated
to increase. as REYATAZ may increase
quetiapine-related toxicity.
Increased plasma concentrations of
quetiapine may lead to coma
(see section 4.3).
Lurasidone REYATAZ is expected to increase plasma Co-administration of lurasidone
levels of lurasidone due to CYP3A4 with REYATAZ is contraindicated
inhibition. as this may increase lurasidone-
related toxicity (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): quetiapine (HOS-086150) protease (HOS-085623) rifabutin (HOS-086262) lead (HOS-085592) ritonavir (HOS-084521) lurasidone (HOS-086148)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 57ec8478d6e13f3ffb31841798fe0270300e604091177c3b0241de94938bc9c0 · Zeichen 26684–31429 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.